Empowered by global genetic expertise

As one of the most diversified and largest genetic testing companies worldwide we are dedicated to transforming the science of genetic information into solutions and hope for patients and their families.

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

Our Latest Scientific News

  • Evidence for inflammation in Fabry’s disease? Headache and muscle involvement responding to corticosteroid and methotrexate treatment

    We report the case of a 38-year-old female patient who had been diagnosed as lupus erythematosus because of generalized muscle and burning pain combined with slightly elevated C-reactive protein (CRP) and antinuclear antibodies (ANA) 1:640. Twelve years later, Fabry’s disease was diagnosed by molecular genetics. Lupus erythematosus and any other co-morbid rheumatologic diseases were falsified retrospectively and prospectively according to international classification criteria. This case illustrates, that in addition to the deposition of lyso-gb3 secondary inflammatory mechanisms may play an important role in the pathophysiology of symptoms in Fabry’s disease.

  • Posterior versus Anterior Circulation Stroke in Young Adults: A Comparative Study of Stroke Aetiologies and Risk Factors in Stroke among Young Fabry Patients

    Although 20–30% of all strokes occur in the posterior circulation, few studies have explored the characteristics of patients with strokes in the posterior compared to the anterior circulation so far. Especially data on young patients is missing. In this secondary analysis of data of the prospective multi-centre European sifap1 study that investigated stroke and transient ischemic attack (TIA) patients aged 18–55 years, we compared vascular risk factors, stroke aetiology, presence of white matter hyperintensities (WMH) and cerebral microbleeds (CMB) between patients with ischaemic posterior circulation stroke (PCS) and those having suffered from anterior circulation stroke (ACS) based on cerebral MRI.

  • Novel GNB1 mutations disrupt assembly and function of G protein heterotrimers and cause global developmental delay in humans

    Global developmental delay (GDD), often accompanied by intellectual disability, seizures and other features is a severe, clinically and genetically highly heterogeneous childhood-onset disorder. In cases where genetic causes have been identified, de-novo mutations in neuronally expressed genes are a common scenario. These mutations can be best identified by exome sequencing of parent-offspring trios. De novo mutations in the guanine nucleotide-binding protein, beta 1 (GNB1) gene, encoding the Gβ1 subunit of heterotrimeric G proteins, have recently been identified as a novel genetic cause of GDD.

CentoWebinar

Join our next webinar "Solving the diagnostic riddle: Diagnosing heterogeneous genetic disorders with whole exome sequencing"

February 28, 2017; 4pm (GMT +1)

Join our webinar

Subscribe to our Newsletter

Our new headquarter in Rostock, CentoNew, is growing rapidly – we started the countdown to our move-in November 2017.

The new headquarter in Rostock will...

Read more

Melbourne, Australia and Rostock/Berlin, Germany: CENTOGENE AG (CENTOGENE) and Genetic Associates announce their strategic collaboration for the Australian/New...

Read more

The Accreditation Committee of the College of American Pathologists has renewed accreditation to CENTOGENE AG based on results of a recent on-site inspection as...

Read more

CENTOGENE participated in this year’s ‘Wissenskarawane’, an educational event aiming to bring insight knowledge about the newest findings in research and...

Read more

CENTOGENE has recently added numerous single gene tests and next generation sequencing (NGS) panels to its portfolio. Our NGS panel compositions always reflect...

Read more

Dr. Arndt Rolfs, CEO CENTOGENE, presented at JP Morgan Healthcare Conference 2017 about CENTOGENE's self-amplifying business model - diagnostics, proprietary...

Read more

For the first time, ever, the Parkinson’s Institute and Clinical Center and CENTOGENE have entered into a collaboration aimed at genetic screening of a large...

Read more

Arndt Rolfs, CEO and founder of CENTOGENE, will present the company’s business model on Wednesday, January 11, 2017, at 4:30 pm PST.

Read more

CENTOGENE announces today a new sequencing facility for rare hereditary disorders, which will use Illumina’s HiSeq X® sequencer.

Read more